Human papillomavirus and endometrial cancer (review of literature and meta-analysis)
https://doi.org/10.17650/1994-4098-2020-16-4-91-99
Abstract
The important role of human papillomavirus (HPV) of high carcinogenic risk in the emergence and development of cervical cancer is undeniable. Approximately 90 % of cases of verified cervical cancer are HPV positive. The level of infection with this virus exceeds that of gonococci, chlamydia and yeast infections. Currently, one of the most discussed issues is the possibility of the association of HPV with the risk of developing malignant neoplasms when localized in organs that are anatomically close to the cervix. One of these localizations is the body of the uterus. It is known that endometrial cancer is based on its pronounced hormone dependence. Nevertheless, many factors are involved in the carcinogenesis of endometrial neoplasms, including genetic and epigenetic disorders, as well as risk factors, which include alimentary, hormonal, hereditary causes. At the same time, a controversial issue is the involvement of HPV in the development of this type of cancer. The data on the presence of HPV in endometrial cancer are extremely contradictory: the researchers claim both the complete absence of the effect of the virus on the development of this type of cancer, and the detection of HPV in 60–80 % of cases of tumors. In this regard, it becomes necessary to systematize the currently available research results on this issue and to conduct a meta-analysis of the association of HPV infection with the risk of endometrial cancer.
About the Authors
M. К. Ibragimova
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
5 Kooperativnyy St., Tomsk 634009
Russian Federation
5 Kooperativnyy St., Tomsk 634009
E. V. Kokorina
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
5 Kooperativnyy St., Tomsk 634009
Russian Federation
5 Kooperativnyy St., Tomsk 634009
М. M. Tsyganov
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
5 Kooperativnyy St., Tomsk 634009
Russian Federation
5 Kooperativnyy St., Tomsk 634009
О. N. Churuksaeva
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
5 Kooperativnyy St., Tomsk 634009
Russian Federation
5 Kooperativnyy St., Tomsk 634009
N. V. Litviakov
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
5 Kooperativnyy St., Tomsk 634009
Russian Federation
5 Kooperativnyy St., Tomsk 634009
References
1. Lortet-Tieulent J., Ferlay J., Bray F. et al. International patterns and trends in endometrial cancer incidence, 1978– 2013. JNCI 2018;110(4):354–61. DOI: 10.1093/jnci/djx214.
2. Abuzarova G.R., Alentov I.I., Anpilogov S.V. et al. Oncogynecology: national leadership. Eds.: A.D. Kaprin, L.A. Ashrafyan, I.S. Stylidi. Moscow: GEOTAR-Media, 2019. 384 p. (In Russ.). DOI: 10.33029/9704-5329-2-ONR-20191-384.
3. Gentry-Maharaj A., Karpinskyj C. Current and future approaches to screening for endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2020;65:79–97. DOI: 10.1016/j.bpobgyn.2019.12.006.
4. Clarke M.A., Long B.J., Del Mar Morillo A. et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Int Med 2018;178(9):1210–22. DOI: 10.1001/jamainternmed.2018.2820.
5. Urick M.E., Bell D.W. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer 2019;19(9):510–21. DOI: 10.1038/s41568-019-0177-x.
6. Johnatty S.E., Tan Y.Y., Buchanan D.D. et al. Family history of cancer predicts endometrial cancer risk independently of Lynch syndrome: implications for genetic counselling. Gynecol Oncol 2017;147(2):381–7. DOI: 10.1016/j.ygyno.2017.08.011.
7. Mester J., Eng C. Cowden syndrome: Recognizing and managing a not-so-rare hereditary cancer syndrome. J Surg Oncol2015;111(1):125–30. DOI: 10.1002/jso.23735.
8. Costas L., Frias-Gomez J., Guardiola M. et al. New perspectives on screening and early detection of endometrial cancer. Int J Cancer 2019;145(12):3194–206. DOI: 10.1002/ijc.32514.
9. O’Hara A.J., Bell D.W. The genomics and genetics of endometrial cancer. Adv Genom Genet 2012;2012(2):33. DOI: 10.2147/AGG.S28953.
10. Bosch F.X. Human papilloma- virus: science and technologies for the elimination of cervical cancer. Exp Op Pharmacother 2011;12(14):2189–204. DOI: 10.1517/14656566.2011.596527.
11. Salazar E., Mercado E., Sojo I. et al. Relationship between estradiol 16α-hydroxylation and human papillomavirus infection in cervical cell transformation. Gynecol Endocrinol 2001;15(5):335–40.
12. Rinaldi S., Plummer M., Biessy C. et al. Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiol Prev Biomarkers 2011;20(12):2532–40. DOI: 10.1158/1055-9965.EPI-11-0753.
13. Spurgeon M.E., den Boon J.A., Horswill M. et al. Human papillomavirus oncogenes reprogram the cervical cancer microenvironment independently of and synergistically with estrogen. Proc Nat Acad Sci 2017;114(43):E9076–E9085. DOI: 10.1073/pnas.1712018114.
14. Ashra- fyan L.A., Kiselev V.I. Tumors of the reproductive organs (etiology and pathogenesis). Moscow: Publishing house Dimitreyd Graphic Group, 2008. 216 p. (In Russ.).
15. Anwar K., Nakakuki K., Imai H. et al. Infection of human papillomavirus (HPV) and p53 over-expression in human female genital tract carcinoma. J Pakistan Med Assoc 1996;46:220–4.
16. Lai C.H., Wang C.Y., Lin C.Y. et al. Detection of human papillomavirus RNA in ovarian and endometrial carcinomas by reverse transcription/polymerase chain reaction. Gynecol Obstet Invest 1994;38(4):276–80. DOI: 10.1159/000292496.
17. Bergeron C., Shah K., Daniel R. et al. Search for human papillomaviruses in normal, hyperplastic, and neoplastic endometria. Obstet Gynecol 1988;72(3Pt 1):383–7.
18. Mackenzie S.L., Gillespie M.T., Scurry J.P. et al. Parathyroid hormone-related protein and human papillomavirus in gynecological tumors. Int J Cancer 1994;56(3):324–30. DOI: 10.1002/ijc.2910560305.
19. Hachisuga T., Matsuo N., Iwasaka T. et al. Human papillomavirus and p53 overexpression in carcinomas of the uterine cervix, lower uterine segment and endometrium. Pathology 1996;28(1):28–31. DOI: 10.1080/00313029600169463.
20. Semczuk A., Stenzel A., Baranowski W. et al. Detection of human papillomavirus types 16 and 18 in human neoplastic endometrium: lack of correlation with established prognostic factors. Oncol Rep 2000;7(4):905–15. DOI: 10.3892/or.7.4.905.
21. Ip S., Wong L.C., Xu C.M. et al. Detection of human papillomavirus DNA in malignant lesions from Chinese women with carcinomas of the upper genital tract. Gynecol Oncol 2002;87(1):104–11. DOI: 10.1006/gyno.2002.6784.
22. Plunkett M.K., Brestovac B., Thompson J. et al. The value of HPV DNA typing in the distinction between adenocarcinoma of endocervical and endometrial origin. Pathology 2003;35(5):397–401. DOI: 10.1080/00313020310001602611.
23. Yang H.J., Liu V.W.S., Tsang P.C.K. et al. Comparison of human papillomavirus DNA levels in gynecological cancers: implication for cancer development. Tumor Biology 2003;24(6):310–316. DOI: 10.1159/000076463.
24. Park T.W., Zivanovic O., Theuerkauf I. et al. The diagnostic utility of human papillomavirus-testing in combination with immunohistochemistry in advanced gynaecologic pelvic tumours: a new diagnostic approach. Int J Oncol 2004;24(4):829–36.
25. Chinen K., Kamiyama K., Kinjo T. et al. Morules in endometrial carcinoma and benign endometrial lesions differ from squamous differentiation tissue and are not infected with human papillomavirus. J Clin Pathol 2004;57:918–26. DOI: 10.1136/jcp.2004.017996.
26. Gingelmaier A., Gutsche S., Mylonas I. et al. Expression of HPV, steroid receptors (ERα, ERβ, PR-A and PR-B) and inhibin/activin subunits (α, βA and βB) in adenosquamous endometrial carcinoma. Anticancer Res 2007;27(4A):2011–7.
27. Ashrafyan L.A., Antonova I.B., Basova I.O. et al. Cancer of the vulva, endometrium, ovaries in postmenopause: implication of an infectious agent. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2007;(4):72–8. (In Russ.).
28. Giatromanolaki A., Sivridis E., Papazoglou D. et al. Human papillomavirus in endometrial adenocarcinomas: infectious agent or a mere “passenger”? Inf Dis Obstet Gynecol 2007;2007:60549. DOI: 10.1155/2007/60549.
29. Fedrizzi E.N., Villa L.L., de Souza I.V. et al. Does human papillomavirus play a role in endometrial carcinogenesis? Int J Gynecol Pathol 2009;28(4):322–7. DOI: 10.1097/PGP.0b013e318199943b.
30. Castle P.E., Fetterman B., Poitras N. et al. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010;115(2):243–8. DOI: 10.1097/AOG.0b013e3181c799a3.
31. Babaeva, N.A., Ashrafyan L.A., Antonova I.B. et al. The role of papillomavirus infection in cancers of female reproductive system after menopause. Vestnik Rossiyskogo nauchnogo tsentra rentgenoradiologii Minzdrava Rossii = Herald of the Russian Scientific Center of Roentgen Radiology 2013;1(13). (In Russ.).
32. Karadayi N., Gecer M., Kayahan S. et al. Association between human papillomavirus and endometrial adenocarcinoma. Medical Oncol 2013;30(3):597. DOI: 10.1007/s12032-013-0597-5.
33. Jones M.W., Onisko A., Dabbs D.J. et al. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors. Int J Gynecol Cancer 2013;23(2):380–4. DOI: 10.1097/IGC.0b013e31825cc8ee.
34. Ashrafyan L.A., Babaeva, N.A., Antonova I.B. et al. Papillomavirus infection and estrogen metabolite imbalance as risk factors for cancer of the female reproductive system. Onkologiya. Zhurnal in. P.A. Gertzena = P.A. Herzen Journal of Oncology 2015;4(1):5–12. (In Russ.)]. DOI: 10.17116/onkolog2015415-12.
35. Zaidan Hassan A., AL-Khalidi S.J., Mohammed B.S. et al. Detection human papilloma virus genotype (16/18) in iraqi women patients with endometrial carcinoma by using chromogen-insitu hybridization (CISH) technique. Iraqi J Cancer Med Genet 2016;9(1):74–81.
36. Zykova T.A., Moiseenko T.I., Frantsiyants E.M. et al. Interrelation of HPV-infection of endometry carcinoma and its clinical-morphological features. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2018;5(5):75–82. (In Russ.)]. DOI: 10.17650/2313-805X-2018-5-3-75-82.
37. Abu-Lubad M.A., Jarajreh D.A., Helaly G.F. et al. Human papillomavirus as an independent risk factor of invasive cervical and endometrial carcinomas in Jordan. J Inf Pub Health 2020;13(4):613–8. DOI: 10.1016/j.jiph.2019.08.017.
38. Moher D., Liberati A., Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8(5):336–41. DOI: 10.1371/journal.pmed.1000097.
39. Liberati A., Altman D.G., Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
40. J Clin Epidemiol 2009;62(10):e1–34. DOI: 10.1371/journal.pmed.1000100.
41. Hisada M., van den Berg B.J., Strickler H.D. et al. Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). Cancer Causes Control 2001;12(4):335–41. DOI: 10.1023/a:1011236803257.
42. Darré T., Aboubakari A.S., Sonhaye L. et al. Primary squamous cell carcinoma of the endometrium associated with human papilloma virus in a young woman: a case report. J Med Case Rep 2019;13(1):167. DOI: 10.1186/s13256-019-2098-4.
43. Kataoka A., Nishida T., Sugiyama T. et al. Squamous cell carcinoma of the endometrium with human papillomavirus type 31 and without tumor suppressor gene p53 mutation. Gynecol Oncol 1997;65(1):180–4. DOI: 10.1006/gyno.1996.4597.
44. Horn L.C., Richter C.E., Einenkel J. et al. p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium. Ann Diagn Pathol 2006;10(4):193–6. DOI: 10.1016/j.anndiagpath.2005.09.001.
45. Kealy W.F., Annis P.G., Barry J.A. et al. Adenoacanthoma of the endometrium: morphological changes induced by human papillomavirus. J Clin Pathol 1990;43:554–9. DOI: 10.1136/jcp.43.7.554.
46. Uccelli A., Wolff T., Valente P. et al. Vascular endothelial growth factor biology for regenerative angiogenesis. Swiss Med Wkly 2019;149:w20011. DOI: 10.4414/smw.2019.20011.
47. Coll-de la Rubia E., Martinez-Garcia E., Dittmar G. et al. Prognostic biomarkers in endometrial cancer: a systematic review and meta-analysis. J Clin Med 2020;9(6):1900. DOI: 10.3390/jcm9061900.
Review
For citations:
Ibragimova M.К., Kokorina E.V., Tsyganov М.M., Churuksaeva О.N., Litviakov N.V. Human papillomavirus and endometrial cancer (review of literature and meta-analysis). Tumors of female reproductive system. 2020;16(4):91-99. (In Russ.) https://doi.org/10.17650/1994-4098-2020-16-4-91-99
Views:
1545
Email this article 